Yesway, Inc.: the filing proof gates that matter now
Yesway, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
1485Results20Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
Pfizer: the post-COVID reset still has to prove durable earnings power
Pfizer reported FY2025 revenue of $62.6 billion and Q1 2026 revenue of $14.5 billion. The thesis depends on portfolio durability, oncology integration, patent cliffs, operating cash flow, debt capacity and pipeline execution.
OpenAGMB: the IPO biotech with two fibrosis readouts before its runway clock matters
AgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
OpenAGL: the Medicare rebound that has to outlast the claims bill
agilon health turned in a stronger Q1 after a brutal FY2025 reset, but the thesis still depends on whether member exits, payor discipline, ACO contribution and CEO execution can hold up against Medicare Advantage medical-cost trend.
OpenAclaris Therapeutics: the three-shot catalyst stack racing the cash clock
Aclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
OpenAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after Humira
Official-source baseline for AbbVie using SEC submissions, FY2025 10-K, Q1 FY2026 10-Q, filed Q1 2026 results, FY2025 results exhibit, proxy materials, annual meeting results, debt filings, and official peer filings.
OpenZymeworks Inc.: the filing proof gates that matter now
Zymeworks Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZhengye Biotechnology Holding Limited: the filing proof gates that matter now
Zhengye Biotechnology Holding Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZurn Elkay Water Solutions Corporation: the filing proof gates that matter now
Zurn Elkay Water Solutions Corporation has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZevra Therapeutics, Inc.: the filing proof gates that matter now
Zevra Therapeutics, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZevia PBC: the filing proof gates that matter now
Zevia PBC has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZura Bio Limited: the filing proof gates that matter now
Zura Bio Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZumiez Inc.: the filing proof gates that matter now
Zumiez Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZoetis: the animal-health compounder has to prove growth after inventory and livestock cycles
Zoetis reported FY2025 revenue of $9.47 billion and Q1 2026 revenue of $2.26 billion, with the official record tying the thesis to companion-animal demand, livestock cycles, product innovation, inventory quality, debt and cash conversion.
OpenZTO Express: China parcel scale with ADR and margin risk attached
ZTO Express reported 2025 revenue of CNY 49.10 billion, operating income of CNY 10.47 billion and operating cash flow of CNY 11.97 billion. The thesis turns on China parcel volume, pricing, network efficiency, cash conversion and ADR governance risk.
OpenYY Group Holding Limited: the filing proof gates that matter now
YY Group Holding Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZenta Group Company Limited: the filing proof gates that matter now
Zenta Group Company Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenAiRWA Inc.: the filing proof gates that matter now
AiRWA Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZentek Ltd.: the filing proof gates that matter now
Zentek Ltd. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenYXT.COM GROUP HOLDING LIMITED: the filing proof gates that matter now
YXT.COM GROUP HOLDING LIMITED has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Open